Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 241

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Rifampin Drug Resistance Tests for Tuberculosis: Challenging the Gold Standard

Open access
Van Deun, Armand, Aung, Kya J. M., Bola, Valentin, Lebeke, Rossin, Hossain, Mohamed Anwar, de Rijk, Willem Bram, Rigouts, Leen, Gumusboga, Aysel, Torrea, Gabriela, de Jong, Bouke C. · 2013 · Journal of Clinical Microbiology

Abstract

The rapid diagnosis of rifampin resistance is hampered by a reported insufficient specificity of molecular techniques for detection of rpoB mutations. Our objective for this study was to document the prevalence and prognostic value of rpoB mutations with unclear phenotypic resistance. The study design entailed sequencing directly from sputum of first failure or relapse patients without phenotypic selection and comparison of the standard retreatment regimen outcome, according to the mutation present. We found that among all rpoB mutations, the best-documented “disputed” rifampin resistance mutations (511Pro, 516Tyr, 526Asn, 526Leu, 533Pro, and 572Phe) made up 13.1% and 10.6% of all mutations in strains from Bangladesh and Kinshasa, respectively. Except for the 511Pro and 526Asn mutations, most of these strains with disputed mutations tested rifampin resistant in routine Löwenstein-Jensen medium proportion method drug susceptibility testing (DST; 78.7%), but significantly less than those with common, undisputed mutations (96.3%). With 63% of patients experiencing failure or relapse in both groups, there was no difference in outcome of first-line retreatment between patients carrying a strain with disputed versus common mutations. We conclude that rifampin resistance that is difficult to detect by the gold standard, phenotypic DST, is clinically and epidemiologically highly relevant. Sensitivity rather than specificity is imperfect with any rifampin DST method. Even at a low prevalence of rifampin resistance, a rifampin-resistant result issued by a competent laboratory may not warrant confirmation, although the absence of a necessity for confirmation needs to be confirmed for molecular results among new cases. However, a result of rifampin susceptibility should be questioned when suspicion is very high, and further DST using a different system (i.e., genotypic after phenotypic testing) would be fully justified.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/jcm.00553-13

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 241

Metadata

Authors
Van Deun, A., Aung, K. J. M., Bola, V., Lebeke, R., Hossain, M. A., de Rijk, W. B., Rigouts, L., Gumusboga, A., Torrea, G., & de Jong, B. C.
Venue
Journal of Clinical Microbiology
Published
2013-08
Volume
51
Issue
8
Pages
2633-2640
ISSN
  • 0095-1137 (ISSN-L)
  • 1098-660X
OpenAlex
W2154844490
Cited by
241
References
3
FWCI
16.83
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rifampin Drug Resistance Tests for Tuberculosis: Challenging the Gold Standard. https://app.cochat.ai/papers/10.1128/jcm.00553-13
The paper
Van Deun, A., Aung, K. J. M., Bola, V., Lebeke, R., Hossain, M. A., de Rijk, W. B., Rigouts, L., Gumusboga, A., Torrea, G., & de Jong, B. C. (2013). Rifampin Drug Resistance Tests for Tuberculosis: Challenging the Gold Standard. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.00553-13

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.